Alterity Therapeutics Ltd
ATH434
Multiple System Atrophy
Resolved
28days ago
Advisory committee · Jun 9, 2026
What's at stake
An FDA advisory committee reviews ATH434 for Multiple System Atrophy around Jun 9, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 15h ago
“Achieving alignment with FDA at the End-of-Phase 2 meeting is a critical step for our Phase 3 program in MSA, providing the clarity we need to advance to this next stage,”